论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
聚乙二醇脂质体阿霉素所致的弥漫性红斑毛囊性皮疹
Authors Zhong L , Hu J , Hu Y , Chen X , Jin J, Li H
Received 24 November 2024
Accepted for publication 8 February 2025
Published 16 April 2025 Volume 2025:18 Pages 949—953
DOI https://doi.org/10.2147/CCID.S508254
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Jeffrey Weinberg
Lingzhi Zhong,* Jian Hu,* Yuqing Hu, Xue Chen, Jiang Jin, Houmin Li
Department of Dermatology, Peking University People’s Hospital, Beijing, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Houmin Li, Email lhoumin@sina.cn
Abstract: Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes and is associated with a high risk of mucocutaneous side effects. The most common cutaneous side effect is hand-foot syndrome, whereas other cutaneous reactions are rarely reported. The pathogenesis of PLD-induced cutaneous reaction is not yet clear. It is presumed that PLD could discharge through sweat or damaged vessels and impair keratinocytes in the basal layer or hair follicles as well as induce lymphocytic inflammation. We report a relatively rare of PLD-induced cutaneous reaction presented as diffuse follicular rashes and intertrigo-like dermatitis. A 56-year-old man, with leiomyosarcoma, developed pruritic and painful follicular erythematous papules with scaling on the trunk and limbs after receiving three cycles of PLD. The patient discontinued the use of PLD because of pain and exacerbation of the eruptions, and then the rashes gradually disappeared. This case highlights the potential pathogenesis underlying this unusual cutaneous reaction related to Pegylated Liposomal Doxorubicin.
Keywords: pegylated liposomal doxorubicin, diffuse follicular rash, intertrigo-like dermatitis